FILING ANALYSIS · THURSDAY, NOVEMBER 12
Bolt Biotherapeutics, Inc. BOLT — 8-K: Results of Operations and Financial Condition
negative
Bolt Biotherapeutics completed a $120 million private placement financing, which will be dilutive to existing shareholders, and announced the acquisition of Prana Therapies, establishing PRA-216 as its primary development focus.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →